Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates
Pacific Biosciences (PACB) delivered earnings and revenue surprises of +29.41% and -9.32%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?